Immunic Statistics
Total Valuation
Immunic has a market cap or net worth of $113.95 million. The enterprise value is $14.71 million.
Market Cap | 113.95M |
Enterprise Value | 14.71M |
Important Dates
The last earnings date was Wednesday, May 8, 2024, before market open.
Earnings Date | May 8, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Immunic has 90.08 million shares outstanding. The number of shares has increased by 122.83% in one year.
Shares Outstanding | 90.08M |
Shares Change (YoY) | +122.83% |
Shares Change (QoQ) | +118.17% |
Owned by Insiders (%) | 7.72% |
Owned by Institutions (%) | 64.26% |
Float | 52.12M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.34 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.09, with a Debt / Equity ratio of 0.01.
Current Ratio | 5.09 |
Quick Ratio | n/a |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -170.20% and return on invested capital (ROIC) is -114.10%.
Return on Equity (ROE) | -170.20% |
Return on Assets (ROA) | -124.70% |
Return on Capital (ROIC) | -114.10% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.22M |
Employee Count | 80 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.22% in the last 52 weeks. The beta is 1.93, so Immunic's price volatility has been higher than the market average.
Beta (1Y) | 1.93 |
52-Week Price Change | -31.22% |
50-Day Moving Average | 1.30 |
200-Day Moving Average | 1.34 |
Relative Strength Index (RSI) | 45.80 |
Average Volume (30 Days) | 428,908 |
Short Selling Information
The latest short interest is 2.82 million, so 3.13% of the outstanding shares have been sold short.
Short Interest | 2.82M |
Short Previous Month | 2.88M |
Short % of Shares Out | 3.13% |
Short % of Float | 5.41% |
Short Ratio (days to cover) | 10.56 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -95.85M |
Pretax Income | -97.92M |
Net Income | -97.92M |
EBITDA | -97.82M |
EBIT | -97.92M |
Earnings Per Share (EPS) | -$1.83 |
Balance Sheet
The company has $97.31 million in cash and $433,000 in debt, giving a net cash position of $96.88 million or $1.08 per share.
Cash & Cash Equivalents | 97.31M |
Total Debt | 433,000 |
Net Cash | 96.88M |
Net Cash Per Share | $1.08 |
Equity / Book Value | 83.58M |
Book Value Per Share | 0.93 |
Working Capital | 82.47M |
Cash Flow
In the last 12 months, operating cash flow was -$75.28 million and capital expenditures -$261,000, giving a free cash flow of -$75.55 million.
Operating Cash Flow | -75.28M |
Capital Expenditures | -261,000 |
Free Cash Flow | -75.55M |
FCF Per Share | -$0.78 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Immunic does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -122.83% |
Shareholder Yield | -122.83% |
Earnings Yield | -87.75% |
FCF Yield | -67.70% |
Analyst Forecast
The average price target for Immunic is $8.50, which is 574.60% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $8.50 |
Price Target Difference | 574.60% |
Analyst Consensus | Strong Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on April 15, 2019. It was a reverse split with a ratio of 1:40.
Last Split Date | Apr 15, 2019 |
Split Type | Reverse |
Split Ratio | 1:40 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |